Obviously, b2a2 BCR-ABL transcript accounts for the two-thirds of majority of all transcripts detected in Syrian CML patients, while one-fourth of the patients expressed the b3a2 transcript either solely or in addition to another transcript. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.